Published in Medical Letter on the CDC and FDA, November 27th, 2005
"We are pleased to have concluded our first human study of oral AT-1001 and delighted that the FDA has granted fast track status to AT-1001. These two events are important additional milestones in our efforts to help those suffering from CD, a disease for which there is no effective treatment," said Blake Paterson, MD, president and CEO of Alba. Alba plans to begin a proof of concept study demonstrating efficacy of AT-1001...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.